What is BacterioScan?
BacterioScan offers the only FDA-cleared UTI detection device designed for fast, accurate, and affordable diagnostics. Employing advanced light scattering technology, the device yields results within 30 to 180 minutes, boasting a sensitivity of 97.7% and a negative predictive value of 99.2%. Its primary objective is to enhance antibiotic stewardship by enabling healthcare providers to swiftly rule out true-negative UTIs, thereby curbing the incidence of unnecessary antibiotic prescriptions. This technology directly addresses the inefficiencies and escalating costs associated with traditional UTI testing methods.
How much funding has BacterioScan raised?
BacterioScan has raised a total of $9.9M across 4 funding rounds:
Unspecified
$2.1M
Series A
$6M
Unspecified
$1.7M
Debt
$150K
Unspecified (2013): $2.1M, investors not publicly disclosed
Series A (2014): $6M led by Missouri Technology, Warson Capital Partners, and BioGenerator
Unspecified (2015): $1.7M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Key Investors in BacterioScan
Missouri Technology
The Missouri Technology Corporation (MTC) is a public-private partnership focused on enhancing entrepreneurship and supporting new high-tech companies, particularly in life sciences and technology sectors, through venture capital and grants.
Warson Capital Partners
Warson Capital Partners is a St. Louis-based firm specializing in capital sourcing, mergers and acquisitions, and financial restructuring for emerging middle-market companies, providing debt and equity capital.
BioGenerator
BioGenerator, based in St. Louis, Missouri, focuses on creating and growing innovative companies through venture investments and comprehensive startup support services.
What's next for BacterioScan?
With a significant enterprise-level funding history and a recent strategic investment, BacterioScan is well-positioned for scaling its operations and expanding market reach. The company's focus on improving antibiotic stewardship through rapid diagnostics aligns with growing healthcare trends towards precision medicine and value-based care. Future growth is likely to involve further clinical validation, broader adoption by healthcare systems, and potential development of additional diagnostic solutions leveraging their core technology. The substantial capital infusion will support these strategic initiatives, driving innovation and market penetration in the competitive diagnostics landscape.
See full BacterioScan company page
